Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension-Reference-Cited by-同舟云学术

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension

Published:2023-12-06 Issue:2 Volume:41 Page:618-637
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Grünig Ekkehard,Rahaghi Franck,Elwing Jean,Vizza Carmine Dario,Pepke-Zaba Joanna,Shen Jieyan,Yao Hua,Hage Antoine,Rosenkranz Stephan,Vonk Madelon,Balasubramanian Vijay,Yuanhua Yang,Yu Zaixin,Lordan James,Cadaret Linda,Grover Rob,Ousmanou Aliou,Seaman Scott,Deng Chunqin,Broderick Meredith,White R. James^ORCID,

Funder

United Therapeutics Corporation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02711-x.pdf

Reference15 articles.

1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;61:2200879.

2. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971–81.

3. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011;30(12):1327–33.

4. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768–74.

5. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–17.